Surrozen, Inc.
SRZN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001824893
In the last 90 days, Surrozen, Inc. insiders filed 0 open-market purchases and 1 sale; 70 institutions reported holding it in 13F filings for Q2 2026, worth $314.5M in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Surrozen, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 27
- +3 vs. Q2 2022
- Shares held
- 21.8M
- +717.5K (+3.4%) vs. Q2 2022
- Total value
- $44.1M
- −$19.1M (−30.2%) vs. Q2 2022
- New holders
- 4
- 3 more added
- Sold out
- 1
- 3 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SRZN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 70 | $314.5M |
| Q1 2026 | 59 | $314.2M |
| Q4 2025 | 55 | $195.1M |
| Q3 2025 | 36 | $81.7M |
| Q2 2025 | 31 | $53.9M |
| Q1 2025 | 30 | $63.5M |
| Q4 2024 | 24 | $35.4M |
| Q3 2024 | 23 | $25.5M |
| Q2 2024 | 21 | $23.1M |
| Q1 2024 | 16 | $15.0M |
| Q4 2023 | 17 | $9.78M |
| Q3 2023 | 25 | $7.90M |
| Q2 2023 | 22 | $8.62M |
| Q1 2023 | 23 | $9.91M |
| Q4 2022 | 26 | $9.36M |
| Q3 2022 | 27 | $44.1M |
| Q2 2022 | 24 | $63.1M |
| Q1 2022 | 30 | $67.4M |
| Q4 2021 | 32 | $153.5M |
| Q3 2021 | 29 | $150.7M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Surrozen, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| The Column Group LLC | 9,248,129 | $18.7M | 4.13% | 00.0% | Unchanged |
| Consonance Capital Management LP | 3,497,500 | $7.07M | 97.05% | 00.0% | Unchanged |
| Baker Bros. Advisors LP | 2,500,000 | $5.05M | 0.03% | 00.0% | Unchanged |
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 1,200,000 | $2.42M | 0.06% | 00.0% | Unchanged |
| Harvard Management Co Inc | 826,852 | $1.67M | 0.21% | 00.0% | Unchanged |
| Euclidean Capital LLC | 802,963 | $1.62M | 1.51% | 00.0% | Unchanged |
| Board of Trustees of The Leland Stanford Junior University | 781,960 | $1.58M | 0.10% | +757,546+3,102.9% | Added |
| Bridger Management, LLC | 700,001 | $1.41M | 0.43% | 00.0% | Unchanged |
| Vanguard Group Inc | 487,278 | $984.0K | 0.00% | +15,299+3.2% | Added |
| Alyeska Investment Group, L.P. | 305,648 | $617.0K | 0.01% | 00.0% | Unchanged |
| Samsara BioCapital, LLC | 300,000 | $606.0K | 0.14% | 00.0% | Unchanged |
| FMR LLC | 252,900 | $511.0K | 0.00% | 00.0% | Unchanged |
| Empery Asset Management, LP | 215,942 | $436.0K | 2.59% | −41,824−16.2% | Reduced |
| Hudson Bay Capital Management LP | 195,400 | $395.0K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 172,370 | $348.0K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 84,628 | $171.0K | 0.00% | −14,500−14.6% | Reduced |
| Prelude Capital Management, LLC | 73,843 | $149.0K | 0.01% | 00.0% | Unchanged |
| State Street Corp | 70,932 | $143.0K | 0.00% | 00.0% | Unchanged |
| Jasper Ridge Partners, L.P. | 46,838 | $95.0K | 0.01% | 00.0% | Unchanged |
| Northern Trust Corp | 35,833 | $72.0K | 0.00% | 00.0% | Unchanged |
| Wolverine Asset Management LLC | 8,725 | $17.0K | 0.00% | +364+4.4% | Added |
| Perceptive Advisors LLC | 6,017 | $12.0K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 5,017 | $10.0K | 0.00% | +5,017 | New |
| UBS Group AG | 787 | $2.00K | 0.00% | +787 | New |
| Tower Research Capital LLC (TRC) | 572 | $1.00K | 0.00% | +572 | New |
| Wells Fargo & Company | 142 | $0 | 0.00% | −4−2.7% | Reduced |
| JPMorgan Chase & Co | 3 | $0 | 0.00% | +3 | New |
| Penserra Capital Management LLC | 0 | $0 | 0.00% | −5,722−100.0% | Sold out |